Analytical and Bioanalytical Chemistry

, Volume 405, Issue 14, pp 4679–4689 | Cite as

Impact of enzymatic and alkaline hydrolysis on CBD concentration in urine

  • Mateus M. Bergamaschi
  • Allan Barnes
  • Regina H. C. Queiroz
  • Yasmin L. Hurd
  • Marilyn A. Huestis
Research Paper

Abstract

A sensitive and specific analytical method for cannabidiol (CBD) in urine was needed to define urinary CBD pharmacokinetics after controlled CBD administration, and to confirm compliance with CBD medications including Sativex—a cannabis plant extract containing 1:1 ∆9-tetrahydrocannabinol (THC) and CBD. Non-psychoactive CBD has a wide range of therapeutic applications and may also influence psychotropic smoked cannabis effects. Few methods exist for the quantification of CBD excretion in urine, and no data are available for phase II metabolism of CBD to CBD-glucuronide or CBD-sulfate. We optimized the hydrolysis of CBD-glucuronide and/or -sulfate, and developed and validated a GC-MS method for urinary CBD quantification. Solid-phase extraction isolated and concentrated analytes prior to GC-MS. Method validation included overnight hydrolysis (16 h) at 37 °C with 2,500 units β-glucuronidase from Red Abalone. Calibration curves were fit by linear least squares regression with 1/x2 weighting with linear ranges (r2 > 0.990) of 2.5–100 ng/mL for non-hydrolyzed CBD and 2.5–500 ng/mL for enzyme-hydrolyzed CBD. Bias was 88.7–105.3 %, imprecision 1.4–6.4 % CV and extraction efficiency 82.5–92.7 % (no hydrolysis) and 34.3–47.0 % (enzyme hydrolysis). Enzyme-hydrolyzed urine specimens exhibited more than a 250-fold CBD concentration increase compared to alkaline and non-hydrolyzed specimens. This method can be applied for urinary CBD quantification and further pharmacokinetics characterization following controlled CBD administration.

Keywords

Cannabidiol Cannabidiol-glucuronide Enzymatic hydrolysis Urine GC-MS 

References

  1. 1.
    Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R (2009) Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 30:515–527CrossRefGoogle Scholar
  2. 2.
    Bergamaschi MM, Queiroz RH, Chagas MH, de Oliveira DC, De Martinis BS, Kapczinski F, Quevedo J, Roesler R, Schroder N, Nardi AE, Martin-Santos R, Hallak JE, Zuardi AW, Crippa JA (2011) Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology 36:1219–1226CrossRefGoogle Scholar
  3. 3.
    Zuardi AW (2008) Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr 30:271–280CrossRefGoogle Scholar
  4. 4.
    Bergamaschi MM, Queiroz RH, Zuardi AW, Crippa JA (2011) Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf 6:237–249CrossRefGoogle Scholar
  5. 5.
    Schubart CD, Sommer IE, van Gastel WA, Goetgebuer RL, Kahn RS, Boks MP (2011) Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophr Res 130:216–221CrossRefGoogle Scholar
  6. 6.
    Morgan CJ, Curran HV (2008) Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry 192:306–307CrossRefGoogle Scholar
  7. 7.
    Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG (1982) Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacol (Berl) 76:245–250CrossRefGoogle Scholar
  8. 8.
    Di Forti M, Morgan C, Dazzan P, Pariante C, Mondelli V, Marques TR, Handley R, Luzi S, Russo M, Paparelli A, Butt A, Stilo SA, Wiffen B, Powell J, Murray RM (2009) High-potency cannabis and the risk of psychosis. Br J Psychiatry 195:488–491CrossRefGoogle Scholar
  9. 9.
    Leweke FM, Schneider U, Radwan M, Schmidt E, Emrich HM (2000) Different effects of nabilone and cannabidiol on binocular depth inversion in Man. Pharmacol Biochem Behav 66:175–181CrossRefGoogle Scholar
  10. 10.
    Karniol IG, Shirakawa I, Kasinski N, Pfeferman A, Carlini EA (1974) Cannabidiol interferes with the effects of delta 9-tetrahydrocannabinol in man. Eur J Pharmacol 28:172–177CrossRefGoogle Scholar
  11. 11.
    Zuardi AW, Hallak JEC, Crippa JAS (2012) Interaction between cannabidiol (CBD) and Delta(9)-tetrahydrocannabinol (THC): influence of administration interval and dose ratio between the cannabinoids. Psychopharmacology 219:247–249CrossRefGoogle Scholar
  12. 12.
    Karschner EL, Darwin WD, Goodwin RS, Wright S, Huestis MA (2011) Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration. Clin Chem 57:66–75CrossRefGoogle Scholar
  13. 13.
    Karschner EL, Darwin WD, McMahon RP, Liu F, Wright S, Goodwin RS, Huestis MA (2011) Subjective and physiological effects after controlled Sativex and oral THC administration. Clin Pharmacol Ther 89:400–407CrossRefGoogle Scholar
  14. 14.
    Mechoulam R, Hanus L (2002) Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects. Chem Phys Lipids 121:35–43CrossRefGoogle Scholar
  15. 15.
    Huestis MA (2005) Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol. Handb Exp Pharmacol 168:657–690CrossRefGoogle Scholar
  16. 16.
    Jiang R, Yamaori S, Takeda S, Yamamoto I, Watanabe K (2011) Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. Life Sci 89:165–170CrossRefGoogle Scholar
  17. 17.
    Wall ME, Brine DR, Perez-Reyes M (1976) Metabolism of cannabinoids in man. In: Braude MC, Szara S (eds) The pharmacology of marihuana. Raven, New York, pp 93–113Google Scholar
  18. 18.
    Paton WD, Pertwee RG (1972) Effect of cannabis and certain of its constituents on pentobarbitone sleeping time and phenazone metabolism. Br J Pharmacol 44:250–261CrossRefGoogle Scholar
  19. 19.
    Harvey DJ, Mechoulam R (1990) Metabolites of cannabidiol identified in human urine. Xenobiotica 20:303–320CrossRefGoogle Scholar
  20. 20.
    Harvey DJ, Martin BR, Paton WD (1976) Identification of the glucuronides of cannabidiol and hydroxycannabidiols in mouse liver. Biochem Pharmacol 25:2217–2219CrossRefGoogle Scholar
  21. 21.
    Mazur A, Lichti CF, Prather PL, Zielinska AK, Bratton SM, Gallus-Zawada A, Finel M, Miller GP, Radominska-Pandya A, Moran JH (2009) Characterization of human hepatic and extrahepatic UDP-glucuronosyltransferase enzymes involved in the metabolism of classic cannabinoids. Drug Metab Dispos 37:1496–1504CrossRefGoogle Scholar
  22. 22.
    Kemp PM, Abukhalaf IK, Manno JE, Manno BR, Alford DD, Abusada GA (1995) Cannabinoids in humans. I. Analysis of delta 9-tetrahydrocannabinol and six metabolites in plasma and urine using GC-MS. J Anal Toxicol 19:285–291CrossRefGoogle Scholar
  23. 23.
    Kemp PM, Abukhalaf IK, Manno JE, Manno BR, Alford DD, McWilliams ME, Nixon FE, Fitzgerald MJ, Reeves RR, Wood MJ (1995) Cannabinoids in humans. II. The influence of three methods of hydrolysis on the concentration of THC and two metabolites in urine. J Anal Toxicol 19:292–298CrossRefGoogle Scholar
  24. 24.
    Abraham TT, Lowe RH, Pirnay SO, Darwin WD, Huestis MA (2007) Simultaneous GC-EI-MS determination of delta9-tetrahydrocannabinol, 11-hydroxy-delta9-tetrahydrocannabinol, and 11-nor-9-carboxy-delta9-tetrahydrocannabinol in human urine following tandem enzyme-alkaline hydrolysis. J Anal Toxicol 31:477–485CrossRefGoogle Scholar
  25. 25.
    Grauwiler SB, Scholer A, Drewe J (2007) Development of a LC/MS/MS method for the analysis of cannabinoids in human EDTA-plasma and urine after small doses of Cannabis sativa extracts. J Chromatogr B Analyt Technol Biomed Life Sci 850:515–522CrossRefGoogle Scholar
  26. 26.
    Scheidweiler KB, Desrosiers NA, Huestis MA (2012) Simultaneous quantification of free and glucuronidated cannabinoids in human urine by liquid chromatography tandem mass spectrometry. Clin Chim Acta 413:1839–1847CrossRefGoogle Scholar
  27. 27.
    GOMA Biotec (2011) GOMA Biotec Product Information Sheet - b-Glucuronidase from Haliotis rufescens (abalone). Product Information:1–2Google Scholar
  28. 28.
    Sigma-Aldrich (2005) Sigma Product Information Sheet—b-Glucuronidase Type IX-A from Escherichia coli. Product Information:1–2Google Scholar
  29. 29.
    Sigma-Aldrich (2008) Sigma Product Information Sheet—b-Glucuronidase Type HP-2 from Helix pomatia. Product Information:1–2Google Scholar
  30. 30.
    Zanchetti G, Floris I, Piccinotti A, Tameni S, Polettini A (2012) Rapid and robust confirmation and quantification of 11-nor-Delta9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH) in urine by column switching LC-MS-MS analysis. J Mass Spectrom 47:124–130CrossRefGoogle Scholar
  31. 31.
    Fernandez Mdel M, Wille SM, Samyn N, Wood M, Lopez-Rivadulla M, De Boeck G (2009) On-line solid-phase extraction combined with liquid chromatography-tandem mass spectrometry for high throughput analysis of 11-nor-Delta9-tetrahydrocannabinol-9-carboxylic acid in urine. J Chromatogr B Analyt Technol Biomed Life Sci 877:2153–2157CrossRefGoogle Scholar
  32. 32.
    Paul BD, Mell LD Jr, Mitchell JM, McKinley RM, Irving J (1987) Detection and quantitation of urinary 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid, a metabolite of tetrahydrocannabinol by capillary gas chromatography and electron impact mass fragmentography. J Anal Toxicol 11:1–5CrossRefGoogle Scholar
  33. 33.
    Robandt PV, Klette KL, Sibum M (2009) Automated solid-phase extraction-liquid chromatography-tandem mass spectrometry analysis of 11-nor-Delta9-tetrahydrocannabinol-9-carboxylic acid in human urine specimens: application to a high-throughput urine analysis laboratory. J Anal Toxicol 33:456–460CrossRefGoogle Scholar
  34. 34.
    Thomas BF, Compton DR, Martin BR (1990) Characterization of the lipophilicity of natural and synthetic analogs of delta 9-tetrahydrocannabinol and its relationship to pharmacological potency. J Pharmacol Exp Ther 255:624–630Google Scholar
  35. 35.
    Garrett ER, Hunt CA (1974) Physiochemical properties, solubility, and protein binding of delta-9-tetrahydrocannabinol. J Pharm Sci 63:1056–1064CrossRefGoogle Scholar
  36. 36.
    Johnson JR, Jennison TA, Peat MA, Foltz RL (1984) Stability of delta-9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC in blood and plasma. J Anal Toxicol 8:202–204CrossRefGoogle Scholar
  37. 37.
    Fairbairn JW, Liebmann JA, Rowan MG (1976) The stability of cannabis and its preparations on storage. J Pharm Pharmacol 28:1–7CrossRefGoogle Scholar
  38. 38.
    Agurell S, Leander K (1971) Stability, transfer and absorption of cannabinoid constituents of cannabis (hashish) during smoking. Acta Pharmaceutica Suecica 8:391–402Google Scholar
  39. 39.
    Gray T, Barnes A, Huestis M (2010) Effect of hydrolysis on identifying prenatal cannabis exposure. Anal Bioanal Chem 397:2335–2347CrossRefGoogle Scholar
  40. 40.
    Harvey DJ, Samara E, Mechoulam R (1991) Comparative metabolism of cannabidiol in dog, rat and man. Pharmacol Biochem Behav 40:523–532CrossRefGoogle Scholar
  41. 41.
    Harvey DJ, Samara E, Mechoulam R (1991) Urinary metabolites of cannabidiol in dog, rat and man and their identification by gas chromatography–mass spectrometry. J Chromatogr 562:299–322CrossRefGoogle Scholar
  42. 42.
    Karschner EL, Barnes AJ, Lowe RH, Scheidweiler KB, Huestis MA (2010) Validation of a two-dimensional gas chromatography mass spectrometry method for the simultaneous quantification of cannabidiol, Delta(9)-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC in plasma. Anal Bioanal Chem 397:603–611CrossRefGoogle Scholar
  43. 43.
    Gaoni Y, Mechoulam R (1966) Hashish VII: the isomerization of cannabidiol to tetrahydrocannabinols. Tetrahedron 22:1481–1488CrossRefGoogle Scholar
  44. 44.
    Adams R, Pease DC, Cain CK, Clark JH (1940) Structure of cannabidiol. VI. Isornerization of cannabidiol to tetrahydrocannabinol, a physiologically active product. Conversion of cannabidiol to cannabinol. J Am Chem Soc 62:2402–2405CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg (outside the USA) 2013

Authors and Affiliations

  • Mateus M. Bergamaschi
    • 1
    • 2
  • Allan Barnes
    • 1
  • Regina H. C. Queiroz
    • 2
  • Yasmin L. Hurd
    • 3
  • Marilyn A. Huestis
    • 1
    • 4
  1. 1.Chemistry and Drug Metabolism, IRP, National Institute on Drug Abuse, NIHBaltimoreUSA
  2. 2.School of Pharmaceutical Sciences of Ribeirão PretoUniversity of São PauloRibeirão PretoBrazil
  3. 3.Pharmacology and Systems Therapeutics, Mount Sinai School of MedicineNew YorkUSA
  4. 4.Chemistry and Drug Metabolism, Intramural Research Program, NIDA, NIH, Biomedical Research CenterBaltimoreUSA

Personalised recommendations